OneMedNet Receives High Six-Figure Add-On Order Under Multiyear Agreement Announced September 30

OneMedNet lands a high six-figure add-on order, boosting data volume by 150%.

What the company is saying

OneMedNet Corporation is announcing a high six-figure add-on order under its multiyear agreement from September 30, 2026, with a commercially scaled AI-enabled precision medicine customer. The company frames this as a rapid expansion, emphasizing that the customer exercised its expansion option within weeks, increasing the contracted data volume by 150%. The narrative stresses the value of OneMedNet’s first-party, longitudinal, de-identified clinical data, sourced from a network of more than 2,300 healthcare partner sites. Aaron Green, President & CEO, highlights customer loyalty, attributing repeat orders to data quality, delivery speed, and depth. The announcement underlines the potential for recurring sublicensing revenue from future end-customer licenses of the partner-sold derivative dataset, while stating that OneMedNet retains source-data rights and restricts end customers from relicensing or reselling the underlying data. The tone is confident and growth-oriented, focusing on operational scale and the platform’s role in supporting AI and precision medicine.

What the data suggests

The add-on order is described as 'high six-figure,' indicating a revenue event between $600,000 and $999,999, though the exact figure is not disclosed. The exercised expansion option increases the customer’s data volume by 150%, signaling strong demand and rapid uptake within weeks of the original agreement. OneMedNet’s operational scale is substantiated by a network of more than 2,300 healthcare partner sites, over 90 million patient journeys, and 270 million studies, all of which are concrete figures. The structure of the agreement allows for potential recurring sublicensing revenue, but no actual recurring revenue or contract values for sublicensing are disclosed. The customer’s use of the data for AI model training and derivative dataset creation is stated, but no quantitative metrics or customer outcomes are provided. The evidence supports a narrative of commercial traction and operational scale, but lacks detailed financial breakdowns or realised downstream revenue.

Analysis

The announcement is generally positive, highlighting a high six-figure add-on order and a 150% increase in data volume under a recently signed multiyear agreement. These are realised, measurable achievements and indicate commercial traction. However, the release also emphasizes the 'potential for recurring sublicensing revenue' and the customer's use of data to build licensable derivative datasets, which are forward-looking and not yet realised. No profitability metrics (net income, EBITDA, operating profit, or cash flow) are disclosed, so the true_signal cannot exceed weak_positive. The language around the scale of the network and future revenue potential is somewhat promotional, but the core facts are supported by the disclosed order and data volume increase. The capital intensity flag is not triggered, as the company is receiving revenue rather than making a large outlay.

Risk flags

• ●The absence of precise dollar figures for the add-on order and the lack of detailed contract terms limit visibility into the true financial impact, making it difficult for investors to assess margin or recurring revenue potential.
• ●The recurring sublicensing revenue is described as a potential future benefit, but no actual sublicensing contracts or realised revenue are disclosed, so future revenue streams are speculative at this stage.
• ●The company’s growth narrative relies heavily on a single customer’s rapid expansion and the broader promise of derivative data sales; if customer demand slows or derivative sales do not materialise, projected recurring revenue could fall short.

Bottom line

OneMedNet’s high six-figure add-on order under its recent multiyear agreement demonstrates immediate commercial traction and a 150% increase in data volume for a key AI-enabled customer. The company’s operational scale is credible, with more than 2,300 partner sites, 90 million patient journeys, and 270 million studies. While the order is a positive signal, the lack of exact revenue figures and the forward-looking nature of sublicensing potential mean that the full financial impact remains uncertain. Investors should focus on whether actual recurring sublicensing revenue emerges and if additional customers follow this expansion pattern. The most important takeaway is that OneMedNet is converting its data assets into near-term revenue, but the durability and scalability of these revenue streams will depend on realised downstream licensing and continued customer growth.

Announcement summary

(NASDAQ:ONMD) OneMedNet Corporation announced it has received a high six-figure add-on order under the multiyear agreement announced on September 30, 2026. The add-on order exercises the expansion option included in the September 30 agreement, increasing data volume by 150% with the commercially scaled AI-enabled precision medicine customer. The September 30 agreement established a multiyear license for de-identified, multimodal, longitudinal clinical Real-World Data. The customer is using the data to train AI-enabled clinical and diagnostic models and to build a licensable derivative dataset for sale into its own channel. The new add-on order was received within weeks of the original announcement, reflecting the customer’s determination that additional data volume is required to support its derivative data offering. Aaron Green, President & CEO of OneMedNet, stated that customers return for repeat data add-on orders due to the speed of delivery, the quality of full-fidelity longitudinal data, and the depth of data sourced from first-party healthcare provider partners. OneMedNet sources its data from a live network of more than 2,300 healthcare partner sites, applying de-identification at the source to meet the standards required for AI foundation models and life sciences commercial data needs. The structure of the agreement retains the potential for recurring sublicensing revenue to OneMedNet on future end-customer licenses of the partner-sold derivative dataset. OneMedNet retains source-data rights, and end customers of the derivative may not relicense or resell the underlying OneMedNet data. The company’s network spans more than 2,300 sites and encompasses over 90 million patient journeys and 270 million studies. OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The iRWD™ platform delivers regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. The platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Disagree with this article?